Suppr超能文献

PCCA 基质混悬剂中临时配制的氢化可的松口服混悬液的物理化学和微生物稳定性

Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt.

机构信息

College of Pharmacy, Xavier University of Louisiana, New Orleans, Louisiana.

出版信息

Int J Pharm Compd. 2021 Sep-Oct;25(5):431-439.

Abstract

Hydrocortisone is indicated in the treatment of primary or secondary adrenal insufficiency. The oral dosage regimen of hydrocortisone needs to be individualized in the treatment of congenital adrenal hyperplasia, especially in pediatric patients. A review of the therapeutic uses of hydrocortisone reveals the need for flexibility in dosing. This flexibility is readily achieved using an oral liquid dosage form. However, no commercial liquid dosage form of hydrocortisone currently exists. Hydrocortisone is commercially available as 5-mg, 10-mg, and 20-mg tablets. An extemporaneously compounded suspension from pure drug powder would provide a convenient option to meet unique patient needs. The purpose of this study was to determine the physicochemical and microbiological stability of extemporaneously compounded hydrocortisone suspensions in PCCA Base, SuspendIt. This base is a sugar-free, paraben-free, dye-free, and gluten-free thixotropic vehicle containing a natural sweetener obtained from the monk fruit. The study design included two hydrocortisone concentrations to provide stability documentation over a bracketed concentration range for eventual use by compounding pharmacists. A robust stability-indicating high-performance liquid chromatographic assay for the determination of the chemical stability of hydrocortisone in SuspendIt was developed and validated. Suspensions of hydrocortisone were prepared in SuspendIt at 1-mg/mL and 20-mg/mL concentrations, selected to represent a range within which the drug is commonly dosed. Samples were stored in plastic amber prescription bottles at two temperature conditions (5°C and 25°C). Samples were assayed initially and on the following days: 7, 15, 28, 45, 60, 91, 120, and 185. Physical data such as pH, viscosity, and appearance were also noted. Microbiological stability was tested. All measurements were obtained in triplicate. A stable extemporaneous product is defined as one that retains at least 90% of the initial drug concentration throughout the sampling period and is protected against microbial growth. The study showed that hydrocortisone concentrations did not go below 94% of the label claim (initial drug concentration) at both temperatures studied. No microbial growth was observed. Viscosity and pH values did not change significantly. This study demonstrates that hydrocortisone is physically, chemically, and microbiologically stable in SuspendIt for 185 days in the refrigerator and at room temperature, thus providing a viable, compounded alternative for hydrocortisone in a liquid dosage form, with an extended beyond-use date to meet patient needs.

摘要

氢化可的松适用于原发性或继发性肾上腺功能不全的治疗。在治疗先天性肾上腺增生症时,需要个体化调整氢化可的松的口服剂量方案,尤其是在儿科患者中。对氢化可的松治疗用途的回顾表明,需要灵活调整剂量。使用口服液体制剂很容易实现这种灵活性。然而,目前市场上没有商品化的氢化可的松液体制剂。氢化可的松以 5mg、10mg 和 20mg 片剂形式供应。由纯药物粉末配制的临时混悬剂将为满足患者的特殊需求提供一个方便的选择。本研究旨在确定 PCCA Base(SuspendIt)中临时配制的氢化可的松混悬剂的物理化学和微生物稳定性。该基础液是一种无糖、无对羟基苯甲酸酯、无染料、无麸质的触变载体,含有一种从罗汉果中提取的天然甜味剂。研究设计包括两种氢化可的松浓度,以提供在最终由药剂师配制使用的范围内的稳定性数据。开发并验证了用于测定氢化可的松在 SuspendIt 中的化学稳定性的稳健、专属性高效液相色谱分析方法。在 1mg/mL 和 20mg/mL 浓度下在 SuspendIt 中制备氢化可的松混悬剂,选择的浓度范围代表了药物常用的剂量范围。样品储存在塑料琥珀色处方瓶中,在两种温度条件(5°C 和 25°C)下储存。样品在初始时以及以下天数进行检测:7、15、28、45、60、91、120 和 185 天。还记录了物理数据,如 pH 值、黏度和外观。测试了微生物稳定性。所有测量均重复 3 次。定义稳定的临时产品为在整个采样期间保留至少 90%初始药物浓度且防止微生物生长的产品。研究表明,在研究的两种温度下,氢化可的松浓度均未低于标签声称(初始药物浓度)的 94%。未观察到微生物生长。黏度和 pH 值没有显著变化。这项研究表明,氢化可的松在 SuspendIt 中在冰箱和室温下 185 天内物理上、化学上和微生物上均稳定,因此为氢化可的松提供了一种可行的、可供选择的液体制剂,其使用期限超过了标签上的使用期限,以满足患者的需求。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验